CLDN6 CAR T cells and CARVac-mediated in vivo expansion demonstrate promising results in patients with CLDN-6-positive advanced solid tumors: The phase 1 BNT211-01 trial

Multi-peptide CoVac-1 vaccine induces T-cell immunity in immunoglobulin-deficient cancer patients

A novel stem cell epigenome biomarker for primary non-response to CD19 CAR T cells in pediatric ALL

Sotorasib demonstrates durable outcomes in pretreated KRAS p.G12C-mutated NSCLC: The 2-year analysis of CodeBreaK 100

NIVO + chemo improves EFS in patients with resectable IB-IIIA NSCLC: the phase 3 CheckMate 816 trial

AFM13-complexed NK cells shown to be safe and promising in the treatment of refractory/relapsed CD30+ lymphoma